Comparative Pharmacology
Head-to-head clinical analysis: MOBAN versus TINDAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOBAN versus TINDAL.
MOBAN vs TINDAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MOBAN (molindone) is an antipsychotic agent with mechanism of action not fully defined, but believed to involve dopamine D2 receptor blockade in the mesolimbic system, with minimal extrapyramidal effects due to weak D2 binding and possible serotonergic modulation.
TINDAL (trimethoprim) inhibits bacterial dihydrofolate reductase (DHFR), preventing the reduction of dihydrofolate to tetrahydrofolate, thereby inhibiting bacterial DNA synthesis.
Oral: 50-100 mg/day in 3-4 divided doses, increase to 225 mg/day for severe conditions; maximum 400 mg/day. IM: 50-100 mg every 4-6 hours; maximum 400 mg/day.
TINDAL (ticarcillin disodium + clavulanate potassium) 3.1 g (ticarcillin 3 g + clavulanic acid 0.1 g) IV every 4-6 hours. Maximum dose: 18 g ticarcillin/0.6 g clavulanic acid per day.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours for parent drug; active metabolite (molindone) half-life ~12-15 hours; steady-state reached in 2-3 days.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment.
Renal: 70-80% as metabolites and unchanged drug; biliary/fecal: ~20%.
Primarily renal excretion of unchanged drug (70-80%) and hepatic metabolism (20-30%).
Category C
Category C
Antipsychotic
Antipsychotic